Compare Stocks → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DNTHNASDAQ:PHARNASDAQ:SIGANASDAQ:SVRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$25.63-2.4%$25.63$6.58▼$33.77$752.21M1.77133,593 shs88,687 shsPHARPharming Group$9.30-2.6%$10.36$9.27▼$16.71$626.30M0.22,185 shs1,094 shsSIGASIGA Technologies$7.61-3.7%$8.45$4.22▼$10.83$541.25M0.951.04 million shs992,566 shsSVRASavara$4.48-5.1%$4.81$2.40▼$5.70$619.09M0.73902,356 shs827,427 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics0.00%+5.52%+8.46%+6.35%+2,562,999,900.00%PHARPharming Group-0.11%-7.00%-3.28%-16.96%-20.51%SIGASIGA Technologies0.00%+2.01%-7.53%+47.77%+36.14%SVRASavara0.00%-3.76%-6.47%-9.86%+80.65%Bible Shocker: Have You Seen Elon Musk’s Miracle? (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNTHDianthus Therapeutics1.226 of 5 stars3.50.00.00.03.21.70.0PHARPharming Group1.9254 of 5 stars3.53.00.00.02.70.00.6SIGASIGA Technologies0.1916 of 5 stars0.01.00.00.02.30.81.3SVRASavara1.276 of 5 stars3.51.00.00.01.11.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics3.00Buy$42.8367.12% UpsidePHARPharming Group3.00Buy$37.00297.85% UpsideSIGASIGA TechnologiesN/AN/AN/AN/ASVRASavara3.00Buy$8.8096.43% UpsideCurrent Analyst RatingsLatest PHAR, SVRA, DNTH, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2024DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/16/2024SVRASavaraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $7.005/13/2024SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.005/10/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $38.005/6/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.004/18/2024DNTHDianthus TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $51.004/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/22/2024DNTHDianthus TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $39.003/22/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $33.003/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$2.83M265.81N/AN/A$12.70 per share2.02PHARPharming Group$245.32M2.55$0.10 per share95.41$3.06 per share3.04SIGASIGA Technologies$139.92M3.87$0.96 per share7.89$2.32 per share3.28SVRASavaraN/AN/AN/AN/A$0.88 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$43.56M-$5.83N/AN/AN/AN/A-20.82%-19.86%8/1/2024 (Estimated)PHARPharming Group-$10.55M-$0.16N/A46.50N/A-4.01%-4.61%-2.18%8/1/2024 (Estimated)SIGASIGA Technologies$68.07M$1.106.927.11N/A50.48%51.97%39.51%8/13/2024 (Estimated)SVRASavara-$54.70M-$0.37N/AN/AN/AN/A-51.95%-40.45%8/8/2024 (Estimated)Latest PHAR, SVRA, DNTH, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023DNTHDianthus Therapeutics-$1.11-$0.71+$0.40-$0.71$0.73 million$0.46 million3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 million3/12/2024Q4 2023SIGASIGA TechnologiesN/A$1.01+$1.01$1.01N/A$116.48 million3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ALatest PHAR, SVRA, DNTH, and SIGA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/12/2024SIGASIGA Technologies$0.603/25/20243/26/20244/11/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A42.5242.52PHARPharming GroupN/A1.431.16SIGASIGA TechnologiesN/A3.052.19SVRASavara0.2214.9014.90OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%PHARPharming Group0.03%SIGASIGA Technologies55.40%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics16.56%PHARPharming Group2.07%SIGASIGA Technologies2.17%SVRASavara4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics5329.35 million24.49 millionNo DataPHARPharming Group38267.34 million65.95 millionNot OptionableSIGASIGA Technologies4571.12 million69.58 millionOptionableSVRASavaraN/A138.19 million131.86 millionOptionablePHAR, SVRA, DNTH, and SIGA HeadlinesRecent News About These CompaniesMay 18 at 5:36 AM | americanbankingnews.comEvercore ISI Lowers Savara (NASDAQ:SVRA) Price Target to $7.00May 16 at 4:05 PM | businesswire.comSavara Announces New Employment Inducement GrantMay 16 at 1:27 PM | marketbeat.comSavara (NASDAQ:SVRA) Price Target Cut to $7.00 by Analysts at Evercore ISIMay 16 at 1:24 AM | americanbankingnews.comQ2 2024 EPS Estimates for Savara Inc (NASDAQ:SVRA) Decreased by AnalystMay 15, 2024 | marketbeat.comQ2 2024 EPS Estimates for Savara Inc Decreased by HC Wainwright (NASDAQ:SVRA)May 15, 2024 | americanbankingnews.comHC Wainwright Weighs in on Savara Inc's FY2028 Earnings (NASDAQ:SVRA)May 15, 2024 | americanbankingnews.comSavara (NASDAQ:SVRA) Receives "Buy" Rating from HC WainwrightMay 14, 2024 | marketbeat.comHC Wainwright Research Analysts Decrease Earnings Estimates for Savara Inc (NASDAQ:SVRA)May 13, 2024 | marketbeat.comSavara (NASDAQ:SVRA) Given "Buy" Rating at HC WainwrightMay 12, 2024 | marketbeat.comSavara Inc (NASDAQ:SVRA) Short Interest Up 28.4% in AprilMay 12, 2024 | americanbankingnews.comSavara (NASDAQ:SVRA) Shares Gap Down to $5.07May 10, 2024 | investorplace.comSVRA Stock Earnings: Savara Misses EPS for Q1 2024May 9, 2024 | businesswire.comSavara Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | marketbeat.comVivo Capital LLC Has $9.82 Million Holdings in Savara Inc (NASDAQ:SVRA)May 7, 2024 | marketbeat.comSavara (NASDAQ:SVRA) Stock Price Up 5.9%May 7, 2024 | businesswire.comSavara to Present at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | ghettoradio.co.keElani Died After Trying To Replace Sauti Sol, SavaraMay 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Savara (SVRA)May 6, 2024 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)May 3, 2024 | indiatoday.inHemant Savara, former minister's son, is BJP's final pick in MaharashtraMay 3, 2024 | markets.businessinsider.comOptimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial SuccessNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up The Next Drug You Take May be Designed By A.I.May 14, 2024 7:30 AMView The Next Drug You Take May be Designed By A.I.All HeadlinesCompany DescriptionsDianthus TherapeuticsNASDAQ:DNTHDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.SIGA TechnologiesNASDAQ:SIGASIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.